Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis

Background— Microvascular damage is one of the first pathological changes in systemic sclerosis. In this study, we investigated the role of Fos-related antigen-2 (Fra-2), a transcription factor of the activator protein-1 family, in the peripheral vasculopathy of systemic sclerosis and examined the underlying mechanisms. Methods and Results— Expression of Fra-2 protein was significantly increased in skin biopsies of systemic sclerosis patients compared with healthy controls, especially in endothelial and vascular smooth muscle cells. Fra-2 transgenic mice developed a severe loss of small blood vessels in the skin that was paralleled by progressive skin fibrosis at 12 weeks of age. The reduction in capillary density was preceded by a significant increase in apoptosis in endothelial cells at week 9 as detected by immunohistochemistry. Similarly, suppression of Fra-2 by small interfering RNA prevented human microvascular endothelial cells from staurosporine-induced apoptosis and improved both the number of tubes and the cumulative tube lengths in the tube formation assay. In addition, cell migration in the scratch assay and vascular endothelial growth factor–dependent chemotaxis in a modified Boyden chamber assay were increased after transfection of human microvascular endothelial cells with Fra-2 small interfering RNA, whereas proliferation was not affected. Conclusions— Fra-2 is present in human systemic sclerosis and may contribute to the development of microvasculopathy by inducing endothelial cell apoptosis and by reducing endothelial cell migration and chemotaxis. Fra-2 transgenic mice are a promising preclinical model to study the mechanisms and therapeutic approaches of the peripheral vasculopathy in systemic sclerosis.

[1]  N. Andrews,et al.  A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. , 1991, Nucleic acids research.

[2]  A. Balmain,et al.  High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model , 2000, Oncogene.

[3]  E. Wagner,et al.  Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1 , 2008, Proceedings of the National Academy of Sciences.

[4]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[5]  D. Pisetsky,et al.  Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. , 2007, Arthritis and rheumatism.

[6]  S. Gay,et al.  The release of microparticles by apoptotic cells and their effects on macrophages , 2005, Apoptosis.

[7]  J. Varga,et al.  Scleroderma: from cell and molecular mechanisms to disease models. , 2005, Trends in immunology.

[8]  Oliver Distler,et al.  Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. , 2007, Arthritis and rheumatism.

[9]  M. Gershwin,et al.  Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. , 1996, The Journal of clinical investigation.

[10]  S. Jimenez,et al.  Lack of endothelial cell apoptosis in the dermis of tight skin 1 and tight skin 2 mice. , 1999, Arthritis and rheumatism.

[11]  V. Foletta.  Transcription factor AP‐1, and the role of Fra‐2 , 1996, Immunology and cell biology.

[12]  A. Koch,et al.  Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis , 2007, Arthritis research & therapy.

[13]  J. Kalden,et al.  Vaskuläre Veränderungen in der Pathogenese der systemischen Sklerose , 2004, Zeitschrift für Rheumatologie.

[14]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[15]  Jordan S. Pober,et al.  Dicer Dependent MicroRNAs Regulate Gene Expression and Functions in Human Endothelial Cells , 2007, Circulation research.

[16]  Hans van Dam,et al.  Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis , 2001, Oncogene.

[17]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .

[18]  E. Wagner,et al.  Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia , 2008, Nature.

[19]  Weibin Shi,et al.  siRNA silencing reveals role of vascular cell adhesion molecule-1 in vascular smooth muscle cell migration. , 2008, Atherosclerosis.

[20]  O. Distler,et al.  [Vascular changes in the pathogenesis of systemic sclerosis]. , 2004, Zeitschrift für Rheumatologie (Print).

[21]  E. Tulchinsky,et al.  Fos family members: regulation, structure and role in oncogenic transformation. , 2000, Histology and histopathology.

[22]  U. Müller-Ladner,et al.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.

[23]  U. Müller-Ladner,et al.  Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. , 2005, Arthritis and rheumatism.

[24]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[25]  D. Abraham,et al.  How does endothelial cell injury start? The role of endothelin in systemic sclerosis , 2007, Arthritis research & therapy.

[26]  M. Matucci-Cerinic,et al.  Mechanisms of vascular damage in SSc--implications for vascular treatment strategies. , 2008, Rheumatology.

[27]  D. Cohen,et al.  Overexpression of fra-2 in transgenic mice perturbs normal eye development , 1998, Oncogene.

[28]  C. Denton,et al.  Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis , 2007, Annals of the rheumatic diseases.